DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Orencia (Abatacept) - Published Studies

 
 



Orencia Related Published Studies

Well-designed clinical trials related to Orencia (Abatacept)

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). [2012]

Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients. [2011.12]

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. [2011.10]

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. [2011.10]

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. [2011.07.30]

Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. [2011.05]

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. [2011.04]

Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. [2011.03]

Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. [2011]

Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. [2010.11]

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. [2010.10]

Abatacept improves health-related quality of life, pain, sleep quality and daily participation in subjects with juvenile idiopathic arthritis. [2010.07.01]

Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. [2010.06]

Evaluation of abatacept in biologic-naive patients with active rheumatoid arthritis. [2010.06]

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). [2010.03]

Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. [2010]

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). [2010]

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. [2009.12]

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. [2009.04]

Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. [2008.11]

Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. [2008.08.01]

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. [2008.08]

Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept. [2008.07]

Decreased external home help use with improved clinical status in rheumatoid arthritis: An exploratory analysis of the Abatacept in Inadequate Responders to Methotrexate (AIM) trial. [2008.04]

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. [2008.04]

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. [2008.04]

Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. [2008.02]

Responsiveness of patient reported outcomes including fatigue, sleep quality and activity limitation and quality of life following treatment with abatacept in patients with rheumatoid arthritis. [2007.09.25]

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. [2007.02]

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. [2007.02]

Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. [2006.11]

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. [2006.10]

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. [2006.09]

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. [2006.06.20]

Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. [2006.04]

Abatacept. [2006]

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. [2005.09.15]

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. [2005.08]

Well-designed clinical trials possibly related to Orencia (Abatacept)

Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. [2013]

A randomized controlled trial to evaluate inhibition of T-cell costimulation in allergen-induced airway inflammation. [2013]

Biologics in Relapsing Polychondritis: A Literature Review. [2011.11.07]

A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. [2011.10]

Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). [2011.05.15]

T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade. [2011.03]

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. [2011.02]

Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. [2011.01]

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. [2011.01]

High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. [2010.11]

Five-year safety and efficacy of belatacept in renal transplantation. [2010.09]

Sequential use of biologic therapy in rheumatoid arthritis. [2010.05]

Innovative therapies for systemic sclerosis. [2010.05]

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). [2010.03]

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). [2010.03]

Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. [2010]

Sequential use of biologic therapy in rheumatoid arthritis. [2010]

Two negative randomized controlled trials in lupus: now what? [2009.05.08]

The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. [2008.10]

The multi-faceted assessment of independence in patients with rheumatoid arthritis: preliminary validation from the ATTAIN study. [2008.05]

Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. [2008.01]

Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. [2007.06.15]

Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. [2007.06]

Item response theory methods can improve the measurement of physical function by combining the modified health assessment questionnaire and the SF-36 physical function scale. [2007.05]

Human clinical trials in lupus nephritis. [2007.01]

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. [2003.11.13]

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. [2002.06]

Other research related to Orencia (Abatacept)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. [2014]

Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes. [2013]

Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. [2013]

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. [2013]

Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. [2013]

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). [2012.01]

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. [2012]

Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. [2012]

Abatacept for Crohn's disease and ulcerative colitis. [2012]

Proposed Severity and Response Criteria for Routine Assessment of Patient Index Data (RAPID3): Results for Categories of Disease Activity and Response Criteria in Abatacept Clinical Trials. [2011.12]

[Efficacy and safety of abatacept in patients with rheumatoid arthritis and no prior treatment with biologics]. [2011.11]

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. [2011.11]

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. [2011.11]

Abatacept: a biologic immune modulator for rheumatoid arthritis. [2011.08]

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. [2011.07]

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. [2011.06]

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. [2011.03]

Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients. [2011]

Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. [2010.10]

Abatacept treatment for rheumatoid arthritis. [2010.09.28]

Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. [2010.08.01]

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: Results of A 12-month exploratory study. [2010.06.08]

Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. [2010.06]

Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. [2010.05]

Efficacy of abatacept in a refractory case of adult-onset Still's disease. [2010.03]

Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data. [2010.03]

Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. [2010]

Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data. [2010]

Abatacept for rheumatoid arthritis: a Cochrane systematic review. [2010]

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. [2009.11]

Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. [2009.11]

Abatacept for rheumatoid arthritis. [2009.10.07]

Relative efficacies: antimalarials to abatacept - the choice is ours. [2009.06]

Abatacept therapy and safety management. [2009.05]

Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. [2009.04]

Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. [2009.04]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014